Articles

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands;Center for Clinical Transfusion Research, Sanquin Research, Leiden, the Netherlands
Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
Service d’Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France
Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece
Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Praha, Czech Republic
Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Department of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
Department of Hematology, Oncology and Clinical Immunology, Universitatsklinik Düsseldorf, Düsseldorf, Germany
Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Clinic of Hematology - Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Department of Clinical Hematology, Hospital da Luz, Lisbon, Portugal
Department of Internal Medicine, Division of Hematology, Merkur University Hospital, Zagreb, Croatia
Service d’Hématologie, Centre Hospitalier Universitaire (CHU) Brabois Vandoeuvre, Nancy, France
Service de Médecine Interne, IUCT-Oncopole, CHU Toulouse, Toulouse, France
Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK
Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Service d’Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université Paris 7, Paris, France
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
St. James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK
Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
Vol. 105 No. 3 (2020): March, 2020 https://doi.org/10.3324/haematol.2018.212217